Novel treatments in diabetes mellitus such as dipeptidyl peptidase IV (DPP4) inhibitors and Glucagon like peptide 1(GlP1) agonists can be theoretically used to control steroid-induced hyperglycemia or diabetes in MM; nevertheless, there are no studies till the present time that have looked into the effect of these new agents on cancer in general and multiple myeloma specifically. This evidence concerns the gene GLP1R and diabetes mellitus.